Artiva Biotherapeutics prices $300M stock and warrant offering
What's the deal? Artiva Biotherapeutics, a clinical-stage biotech developing cell therapies for autoimmune diseases, has priced a $300M underwritten offering of common stock and pre-funded warrants. The San Diego-based company is selling roughly 23.9 million shares at $11.52 each, plus pre-funded warrants for about 2.2 million additional shares.
The offering drew participation from a roster of notable investors including Caligan Partners, Venrock Healthcare Capital Partners, RA Capital Management, Viking Global Investors, Blackstone Multi-Asset Investing, and RTW Investments, among others. The deal is expected to close around May 11, 2026.
Jefferies, TD Cowen, and Cantor are acting as joint book-running managers.
Why now? Artiva is a clinical-stage company, meaning it burns cash as it advances therapies through trials. A $300M raise at this stage suggests it needs capital to fund upcoming development milestones — likely late-stage trials or manufacturing buildout for its autoimmune disease pipeline.
The company is leveraging a shelf registration statement declared effective in August 2025, giving it the flexibility to tap public markets when conditions are favourable.
What could go wrong? Issuing roughly 26 million new shares dilutes existing shareholders. For a clinical-stage biotech with no approved products yet, the risk is straightforward: if trials disappoint, the capital raised today buys time but not success.
The pre-funded warrant structure — where some investors pay the full share price minus a nominal $0.0001 exercise price — suggests certain participants wanted to stay below ownership thresholds, which can signal caution about governance influence even as they commit significant capital.
The signal: A $300M raise with heavyweight institutional backers like Blackstone and Viking Global reflects strong investor appetite for autoimmune cell therapy plays. The sector has gained momentum as companies race to apply cell therapy platforms — originally built for oncology — to the much larger autoimmune disease market.
The calibre of the investor syndicate here is notable. When firms like RA Capital and EcoR1 show up alongside crossover investors like Viking and Blackstone, it typically signals conviction that a company's clinical data could support a significant commercial opportunity.
Read more: globenewswire.com
